Last reviewed · How we verify
NCT02190786
Phase II Exploratory Clinical Study of KUX-1151
Phase 2 trial testing KUX-1151 in Hyperuricemia. Completed.
Quick facts
| Lead sponsor | Kissei Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Primary completion | 1 March 2015 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- KUX-1151 — full drug profile →
Conditions studied
- Hyperuricemia — all drugs for Hyperuricemia →
Sponsor
Kissei Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 20 to 64, any sex, with Hyperuricemia. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Proportion of subjects achieving serum uric acid level ≤ 6 mg/dL
Time frame: 14 weeks -
Percent change from baseline in serum uric acid level
Time frame: 14 weeks -
Change from baseline in serum uric acid level
Time frame: 14 weeks
Sponsor's own description
The purpose of this study is to investigate the efficacy, safety and pharmacokinetics of multiple oral administration of KUX-1151 in patients with hyperuricemia including gout.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
SLC transporters as therapeutic targets: emerging opportunities.
Lin L, Yee SW, Kim RB, Giacomini KM. · · 2015 · cited 653× · PMID 26111766 · DOI 10.1038/nrd4626
Verify or expand the search:
- PubMed search for NCT02190786
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hyperuricemia
Currently open trials in the same condition.
- NCT07144332 — This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In Ord · recruiting
- NCT07400549 — Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support T · NA · recruiting
- NCT06859073 — A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia · Phase 1 · recruiting
- NCT06463561 — CPAP Effect on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive Sleep Apnea · Phase 4 · recruiting
- NCT06729853 — PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function · Phase 1, PHASE2 · active not recruiting
Other Kissei Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT06757257 — Special Drug Use-results Survey for Long-term Use (Fostamatinib) · recruiting
- NCT05831670 — An Early Phase 2 Clinical Study of KSP-0243 · Phase 2 · completed
- NCT05445167 — A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain · Phase 3 · completed
- NCT05440383 — A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia · Phase 3 · completed
- NCT06758271 — Special Drug Use-results Survey for Long-term Use（Avacopan） · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02190786 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kissei Pharmaceutical Co., Ltd.
- Last refreshed: 16 October 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02190786.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing